论文部分内容阅读
目的观察诺和锐30治疗2型糖尿病的临床效果。方法选择2011年7月—2013年12月收治的2型糖尿病患者57例,给予餐前皮下注射诺和锐30治疗,3个月后复查患者空腹血糖(fasting plasma glucose,FPG)、餐后2小时血糖(2 h ours plasma glucose,2h PG)及HbA1c,观察治疗效果。计量资料采用t检验,以P<0.05为差异有统计学意义。结果治疗后FPG、2 h PG、HbA1c分别为(5.52±1.36)、(7.61±1.64)mmol/L、(6.71±0.77)%,与治疗前比较差异均有统计学意义(t=12.895、13.897、18.363,均P<0.05)。治疗期间所有患者均未发生明显低血糖反应,无严重不良反应。结论诺和锐30治疗2型糖尿病临床疗效确切,不良反应小,使用方便,值得临床推广应用。
Objective To observe the clinical effect of Novo-Rui 30 on type 2 diabetes mellitus. Methods Fifty-seven patients with type 2 diabetes mellitus who were admitted from July 2011 to December 2013 were enrolled in this study. Nuo or Rui 30 was given subcutaneously before meals. After 3 months, fasting plasma glucose (FPG), postprandial 2 Hour 2 h plasma glucose (2h PG) and HbA1c, to observe the therapeutic effect. Measurement data using t test, P <0.05 was considered statistically significant. Results The levels of FPG, 2 h PG and HbA1c were (5.52 ± 1.36) and (7.61 ± 1.64) mmol / L and (6.71 ± 0.77)% respectively after treatment, which were significantly different from those before treatment (t = 12.895 and 13.897 , 18.363, all P <0.05). During treatment, no obvious hypoglycemia occurred in all the patients and no serious adverse reactions occurred. Conclusion Nuo-Rui-Rui 30 treatment of type 2 diabetes clinical efficacy, adverse reactions, easy to use, it is worthy of clinical application.